Cerus Announces Collaboration Agreement With Nipro for Innovative INTERCEPT Red Blood Cell System Component

  Cerus Announces Collaboration Agreement With Nipro for Innovative INTERCEPT
  Red Blood Cell System Component

Business Wire

CONCORD, Calif. -- April 29, 2014

Cerus Corporation (NASDAQ: CERS) announcedtoday that it has entered into a
collaboration agreement with the Nipro Corporation’s pharmaceutical division
to develop technology to support commercial implementation of the INTERCEPT
System for Red Blood Cells (RBCs). Under the agreement, the companies will
leverage Nipro’s proprietary technology to develop a set that enables the
mixing and delivery of key chemical compounds to the red cell component, a
process which is integral to the pathogen inactivation technology for RBCs.

“The intent is to have a disposable kit for red cells that is very easy to use
and operationally efficient in both large and small blood centers. With a
simple manual squeeze of a connected double bag, active components in the kit
are reconstituted in a solution to begin the inactivation process,” said Nina
Mufti, Cerus’ vice president of development. “We are excited about our
partnership with Nipro, a company known for its innovation, and believe that
this collaboration sets the stage for a broader arrangement for the
large-scale production of this key component of the INTERCEPT red cell
disposable set.”

Nipro Corporation’s pharmaceutical business specializes in producing
innovative kit products that maximimize operational ease-of-use, including
prefilled syringes and liquid/powder double-bag kits. Nipro Group (Nipro
Corporation and its affiliate companies) has one of the largest contract
manufacturing operations in Japan, and manufactures drug products for more
than 70 companies in Japan and abroad.


Cerus Corporation is a biomedical products company focused in the field of
blood safety. Cerus currently markets and sells the INTERCEPT Blood System for
both platelets and plasma in Europe, the Commonwealth of Independent States,
the Middle East and selected countries in other regions around the world. In
the United States, Cerus is seeking regulatory approval of the INTERCEPT Blood
System for plasma and platelets. The INTERCEPT red blood cell system is in
clinical development.

See http://www.cerus.com for more information.

INTERCEPT and the INTERCEPT Blood System are trademarks of Cerus Corporation.

This press release contains forward-looking statements. Any statements
contained in this press release that are not statements of historical fact may
be deemed to be forward-looking statements, including, without limitation,
statements relating to the results of the current collaboration, and potential
future collaborations, between Nipro and Cerus. These forward-looking
statements are based upon Cerus’ current expectations. Actual results could
differ materially from these forward-looking statements as a result of certain
factors, including, without limitation, risk that Cerus will be successful in
advancing, capitalizing and monetizing red blood cell system; that Cerus can
raise sufficient capital to support its product development and
commercialization efforts; that product development efforts and clinical
studies can be performed in an efficient and effective manner; and risks
associated with dependence on third-party collaborators to support development
activities as well as other risks detailed in the Cerus' filings with the
Securities and Exchange Commission (SEC), including in Cerus' annual report on
Form 10-K for the year ended December 31, 2013, filed with the SEC on March 7,
2014. You are cautioned not to place undue reliance on these forward-looking
statements, which speak only as of the date of this press release. Cerus does
not undertake any obligation to update any forward-looking statements as a
result of new information, future events, changed assumptions or otherwise.


Cerus Corporation
Lainie Corten, 925-288-6319
Sr Director, Global Marketing & Investor Relations
Press spacebar to pause and continue. Press esc to stop.